Shouyao Holdings (Beijing) Co., LTD.

688197

CNE1000062V6

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-07-04 pm EDT			5-day change	1st Jan Change
41.9 ^CNY	+6.75%		-4.03%	-24.08%

Apr. 28	Shouyao Holdings Co., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 23	1,859,000 A Shares of Shouyao Holdings Co., LTD. are subject to a Lock-Up Agreement Ending on 23-MAR-2024.	CI

Shouyao Holdings Co., LTD.(XSSC:688197) added to S&P Global BMI Index

September 18, 2023 at 12:00 am EDT

Shouyao Holdings (Beijing) Co., LTD.(XSSC:688197) added to S&P Global BMI Index

Latest news about Shouyao Holdings (Beijing) Co., LTD.

Shouyao Holdings Co., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 28	CI
1,859,000 A Shares of Shouyao Holdings Co., LTD. are subject to a Lock-Up Agreement Ending on 23-MAR-2024.	Mar. 22	CI
China Healthcare Stocks Rally on Hopes for Government Support	Mar. 14	DJ
Shouyao Holdings Co., LTD. Reports Earnings Results for the Full Year Ended December 31, 2023	Jan. 30	CI
Shouyao Receives Hospital Approval for the Trial of Lung Cancer Drug	Dec. 26	MT
Shouyao Holdings Co., LTD. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Shouyao Holdings Co., LTD.(XSSC:688197) added to S&P Global BMI Index	23-09-18	CI
Shouyao Holdings Co., LTD. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-21	CI

Chart Shouyao Holdings (Beijing) Co., LTD.

Duration

Period

Chart Shouyao Holdings (Beijing) Co., LTD.

More charts

Shouyao Holdings Co Ltd is a China-based company mainly engaged in the research and development of innovative drugs. The Company's main business is the research and development of small molecule innovative drugs in the clinical stage. The Company's main products include anaplastic lymphoma kinase (ALK) kinase inhibitors, selective inhibitors and others. The Company's pharmaceutical products are used in key tumor indications such as non-small cell lung cancer, lymphoma, hepatocellular carcinoma, pancreatic cancer, thyroid cancer, ovarian cancer, and leukemia, as well as disease areas such as type II diabetes. The Company mainly operates in the domestic market.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

41.9 CNY

Average target price

67 CNY

Spread / Average Target

+59.90%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SHOUYAO HOLDINGS (BEIJING) CO., LTD.	-24.08%	857M
ELI LILLY AND COMPANY	+56.89%	823B
NOVO NORDISK A/S	+39.52%	627B
JOHNSON & JOHNSON	-6.55%	353B
MERCK & CO., INC.	+15.99%	320B
ABBVIE INC.	+7.92%	295B
ASTRAZENECA PLC	+13.74%	239B
NOVARTIS AG	+13.83%	220B
ROCHE HOLDING AG	-0.49%	219B
AMGEN INC.	+7.94%	167B

Other Pharmaceuticals

Shouyao Holdings (Beijing) Co., LTD.

Equities

688197

CNE1000062V6

Pharmaceuticals

Shouyao Holdings Co., LTD.(XSSC:688197) added to S&P Global BMI Index

Latest news about Shouyao Holdings (Beijing) Co., LTD.

Chart Shouyao Holdings (Beijing) Co., LTD.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals